← Back to Clinical Trials
Recruiting NCT06962293

NCT06962293 Magnetic Guided Counetrtraction During Endoscopic Submucosal Dissection

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06962293
Status Recruiting
Phase
Sponsor Chinese University of Hong Kong
Condition Early Gastric Cancer
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2025-05-09
Primary Completion 2026-05-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
MAG-ESD assisted ESD

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2025-05-09 with a primary completion date of 2026-05-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Endoscopic submucosal dissection (ESD) is a technique that allows curative treatment of early gastrointestinal neoplasia with organ preservation. However, it is a technically demanding procedure. Tissue traction plays a vital role in facilitating the visualization of the cutting line and the submucosal vessels, which usually only relies on the hood attached to the tip of the endoscope. However, when dealing with flat or large lesions, the absence of reliable traction in ESD contributes to its technical complexity and prolongs procedure duration. Various traction devices and techniques have been developed to provide tension for the dissection plane and optimal visibility during ESD. Most of these only provide static traction from a fixed angle, thus the effect of traction diminishes when the dissection continues. In contrast to the aforementioned traction methods, magnetic traction offers the ability to externally manipulate an internal magnetic retractor, simplifying the internal workspace. The proposed magnetic retractor is composed of a detachable clip from an hemoclip is affixed to a magnetic element. By adjusting the position of the external magnetic source, the magnetic retractor automatically couples and aligns with it, enabling simultaneous dynamic directional control during the ongoing ESD operation. A novel robotic magnetic countertraction system was developed (MAG-ESD). The system consists of two sections: an external permanent magnetic source and the disposable magnetic retractor. The external permanent magnetic source is composed by a large external permanent magnet (EPM) which held by robot arm to externally control the locomotion of the magnetic retractor within patient. The disposable magnetic retractor is a consumable surgical instrument that modified from a commercial hemoclip, which has small magnets hangs on the clip legs. The design of the disposable magnetic retractor eliminates the need for endoscope withdrawal which can be inserted through the instrument channel from the handle during ESD operations, like other common instruments. In the current pilot study, the novel MAG-ESD counetrtraction system would be tested in 20 patients who undergo gastric and colonic ESD, with the aim of evaluating the system efficacy and safety.

Eligibility Criteria

Inclusion Criteria: * Patient with superficial gastric or colorectal lesions, scheduled for endoscopic submucosal dissection (ESD). Exclusion Criteria: 1. Patient who refused to participate 2. Other cases deemed by the examining physician as unsuitable for safe treatment The robotic magnetic countertraction system consist of a strong permanent magnet which always have a strong magnetic field in its surrounding. Therefore, we follow the MRI precautions for the strict safety measurement: 3. Patient who had a cardiac pacemaker. 4. Patient who had any metallic implant or device, such as drug pump, stent, etc. 5. Patient who has or had any metal fragments in eye or any other part of body, or had ever worked with metal.

Contact & Investigator

Central Contact

Hon Chi Yip, MBChB, FRCSEd (General)

✉ hcyip@surgery.cuhk.edu.hk

📞 +85235052956

Frequently Asked Questions

Who can join the NCT06962293 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Early Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06962293 currently recruiting?

Yes, NCT06962293 is actively recruiting participants. Contact the research team at hcyip@surgery.cuhk.edu.hk for enrollment information.

Where is the NCT06962293 trial being conducted?

This trial is being conducted at Hong Kong, Hong Kong.

Who is sponsoring the NCT06962293 clinical trial?

NCT06962293 is sponsored by Chinese University of Hong Kong. The trial plans to enroll 20 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology